Literature DB >> 27324281

Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials.

Paolo A Ascierto1, Georgina V Long2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27324281     DOI： 10.1016/S1470-2045(16)30017-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  11 in total

1.  Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma.

Authors:  Ester Simeone; Antonio Maria Grimaldi; Lucia Festino; Diana Giannarelli; Vito Vanella; Marco Palla; Marcello Curvietto; Assunta Esposito; Giuseppe Palmieri; Nicola Mozzillo; Paolo Antonio Ascierto
Journal:  Oncoimmunology       Date:  2017-01-19       Impact factor: 8.110

Review 2.  Do immune checkpoint inhibitors need new studies methodology?

Authors:  Roberto Ferrara; Sara Pilotto; Mario Caccese; Giulia Grizzi; Isabella Sperduti; Diana Giannarelli; Michele Milella; Benjamin Besse; Giampaolo Tortora; Emilio Bria
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 3.  Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

Authors:  Volker M Lauschke; Yitian Zhou; Magnus Ingelman-Sundberg
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

Review 4.  Immunological effects of BRAF+MEK inhibition.

Authors:  Paolo A Ascierto; Reinhard Dummer
Journal:  Oncoimmunology       Date:  2018-07-23       Impact factor: 8.110

5.  Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy.

Authors:  David Levy; Haryana M Dhillon; Anna Lomax; Michael Marthick; Catriona McNeil; Steven Kao; Judith Lacey
Journal:  Support Care Cancer       Date:  2018-09-04       Impact factor: 3.603

Review 6.  Targeted agents and immunotherapies: optimizing outcomes in melanoma.

Authors:  Jason J Luke; Keith T Flaherty; Antoni Ribas; Georgina V Long
Journal:  Nat Rev Clin Oncol       Date:  2017-04-04       Impact factor: 66.675

7.  Long-term outcomes in oral cavity squamous cell carcinoma with adjuvant and salvage radiotherapy after surgery.

Authors:  Evangelia Katsoulakis; Jonathan E Leeman; Benjamin H Lok; Weiji Shi; Zhigang Zhang; Jillian C Tsai; Sean M McBride; Eric J Sherman; Marc Cohen; Richard Wong; Ian Ganly; Nancy Y Lee; Nadeem Riaz
Journal:  Laryngoscope       Date:  2018-04-10       Impact factor: 3.325

8.  Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective.

Authors:  Casey Quinn; Louis P Garrison; Anja K Pownell; Michael B Atkins; Gérard de Pouvourville; Kevin Harrington; Paolo Antonio Ascierto; Phil McEwan; Samuel Wagner; John Borrill; Elise Wu
Journal:  J Immunother Cancer       Date:  2020-07       Impact factor: 13.751

Review 9.  Evolving impact of long-term survival results on metastatic melanoma treatment.

Authors:  Olivier Michielin; Michael B Atkins; Henry B Koon; Reinhard Dummer; Paolo Antonio Ascierto
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751

10.  Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016.

Authors:  Paolo A Ascierto; Bruno Daniele; Hans Hammers; Vera Hirsh; Joseph Kim; Lisa Licitra; Rita Nanda; Sandro Pignata
Journal:  J Transl Med       Date:  2017-10-11       Impact factor: 5.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.